Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir

Journal of Clinical Gastroenterology

Volumn 48, Issue 3, 2014, Pages 272-278

  Kim, Mi Na ^a   Kim, Seung Up ^a,b   Park, Jun Yong ^a,b   Kim, Do Young ^a,b   Han, Kwang Hyub ^a,b,c   Chon, Chae Yoon ^a,b   Ahn, Sang Hoon ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Chronic hepatitis B; Entecavir; Liver stiffness; Liverrelated events; Transient elastography

Indexed keywords

ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOPSY; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; ELASTICITY IMAGING TECHNIQUES; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894054800     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31829a7247     Document Type: Article

References (42)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008; 359:1486-1500.
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:35-47.
3. Di Marco V, Lo Iacono O, Camma C, et al. The long-Term course of chronic hepatitis B. Hepatology. 1999;30:257-264.
4. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients. J Hepatol. 1998;28:930-938.
5. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675-680.
6. Tanaka R, Itoshima T, Nagashima H. Follow-up study of 582 liver cirrhosis patients for 26 years in Japan. Liver. 1987;7: 316-324.
7. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009;50:661-662.
8. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
9. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162.
10. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21:77-82.
11. Kim SU, Lee JH, Kim do Y, et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One. 2012;7:e36676.
12. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
13. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618.
14. Perrault J, McGill DB, Ott BJ, et al. Liver biopsy: Complications in 1000 inpatients and outpatients. Gastroenterology. 1978;74:103-106.
15. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med. 1993;118:96-98.
16. Ganne-Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006;44: 1511-1517.
17. Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol. 2012;18:163-173.
18. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705-1713.
19. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53: 885-894.
20. Kim do Y, Kim SU, Ahn SH, et al. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci. 2009;54:1758-1763.
21. Kim SU, Han KH, Nam CM, et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol. 2008;23:1722-1727.
22. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology. 1988;8:493-496.
23. Patch D, Dagher L. Acute variceal bleeding: General management. World J Gastroenterol. 2001;7:466-475.
24. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(SUPPL6):vi1-vi12.
25. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515-525.
26. Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis. 1998;27:669-674; quiz 675-666.
27. Gines P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol. 1999;10:1833-1839.
28. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
29. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-Term lamivudine therapy. Gastroenterology. 2003;124:105-117.
30. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-1751.
31. Chang TT, Liaw YF, Wu SS, et al. Long-Term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-893.
32. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531.
33. Fung SK, Lok AS. Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol. 2005;42(suppl):S54-S64.
34. Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J Hepatol. 2010;53:348-356.
35. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-430.
36. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
37. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-1801.
38. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347: 168-174.
39. Kim SU, Oh HJ, Wanless IR, et al. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol. 2012;57:556-563.
40. Kim BK, Kim do Y, Han KH, et al. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol. 2011;106:1654-1662, 1730.
41. Kim BK, Park YN, Kim do Y, et al. Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement. Digestion. 2012;85:219-227.
42. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29:242-247.